menu

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

3 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.

    This course consists of the following:

    • Chapter 1: The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
    • Chapter 2: Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
    • Chapter 3: Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA
  • How to obtain your CME certificate

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate (if your score >70%)
  • Learning Objectives

    After watching these three videos, the learner should be able to:

    • Identify barriers of implementing findings from clinical trials and recommendations in guidelines for treatment of HFrEF
    • Interpret findings from CV outcomes trials with SGLT2i in HF patients
    • Describe details of ongoing trials with SGLT2i in HF patients across the entire spectrum of LVEF
  • Expert faculty

    • Prof. John McMurray, MD - Glasgow, UK
    • Prof. Carolyn Lam, MD, PhD - Singapore
    • Prof. Scott Solomon, MD - Boston, MA, USA
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with heart failure.

  • CME accreditation

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

  • Questions

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.

    This course consists of the following:

    • Chapter 1: The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
    • Chapter 2: Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
    • Chapter 3: Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA
  • How to obtain your CME certificate

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate (if your score >70%)
  • Learning Objectives

    After watching these three videos, the learner should be able to:

    • Identify barriers of implementing findings from clinical trials and recommendations in guidelines for treatment of HFrEF
    • Interpret findings from CV outcomes trials with SGLT2i in HF patients
    • Describe details of ongoing trials with SGLT2i in HF patients across the entire spectrum of LVEF
  • Expert faculty

    • Prof. John McMurray, MD - Glasgow, UK
    • Prof. Carolyn Lam, MD, PhD - Singapore
    • Prof. Scott Solomon, MD - Boston, MA, USA
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with heart failure.

  • CME accreditation

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

  • Questions

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Sep 2023